80 / 1674
80 / 1674
•
Level of evidence 1A for clinical utility of MammaPrint® in the clinical –
high group
•
C-High/g-Low (48% N+ !) show a 5-yr DMFS >94% (with or without CT)
•
In the whole population: 14% reduction in CT prescription
•
In the c-High subgroup: 46% reduction in CT prescription
